Risperidone

Generic Name
Risperidone
Brand Names
Perseris, Risperdal, Rykindo, Uzedy, Okedi
Drug Type
Small Molecule
Chemical Formula
C23H27FN4O2
CAS Number
106266-06-2
Unique Ingredient Identifier
L6UH7ZF8HC
Background

Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...

Indication

Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...

Associated Conditions
Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state
Associated Therapies
-
Clinical Trials
Related News

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

First Posted Date
2006-06-16
Last Posted Date
2010-02-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
628
Registration Number
NCT00337662
Locations
🇷🇺

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

First Posted Date
2006-05-29
Last Posted Date
2018-07-10
Lead Sponsor
Northwell Health
Target Recruit Count
357
Registration Number
NCT00330863
Locations
🇺🇸

University of California, Los Angeles, Los Angeles, California, United States

🇺🇸

Medical College of Georgia, Department of Psychiatry, Augusta, Georgia, United States

🇺🇸

Harvard Medical School -- Dr. John C. Corrigan Community Mental Health Center, Fall River, Massachusetts, United States

and more 5 locations

Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: Aripiprazole
Drug: Risperidone
First Posted Date
2006-05-03
Last Posted Date
2016-09-08
Lead Sponsor
Northwell Health
Target Recruit Count
198
Registration Number
NCT00320671
Locations
🇺🇸

The Zucker Hillside Hospital, Glen Oaks, New York, United States

Identification and Treatment of the Liability to Develop Schizophrenia

Phase 4
Conditions
Schizophrenia
First Posted Date
2006-03-22
Last Posted Date
2009-06-24
Lead Sponsor
Central South University
Target Recruit Count
100
Registration Number
NCT00305474
Locations
🇨🇳

Mental Health Institute, Changsha, Hunan, China

Effect of Quetiapine on Negative Symptoms and Cognition

Phase 3
Completed
Conditions
Schizophrenia
First Posted Date
2006-03-22
Last Posted Date
2009-06-11
Lead Sponsor
AstraZeneca
Target Recruit Count
45
Registration Number
NCT00305422
Locations
🇩🇪

Research Site, Munich, Germany

Risperidone Augmentation for Treatment-Resistant Aggression in ADHD

Phase 4
Completed
Conditions
Aggression
First Posted Date
2006-03-01
Last Posted Date
2006-03-16
Lead Sponsor
Armenteros, Jorge L., M.D., P.A.
Target Recruit Count
25
Registration Number
NCT00297739
Locations
🇺🇸

Jorge L. Armenteros, M.D., P.A., Coral Gables, Florida, United States

Risperidone Plus Mood Stabilizer in Treatment of Mixed Mania

Phase 4
Completed
Conditions
Bipolar Disorder
Interventions
Drug: Risperidone
First Posted Date
2006-02-20
Last Posted Date
2018-06-14
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
45
Registration Number
NCT00294255
Locations
🇺🇸

University of Texas Health Science Center, San Antonio, Texas, United States

Risperidone Augmentation in Patients With Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: placebo
Drug: Risperidone
First Posted Date
2006-02-10
Last Posted Date
2013-10-31
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
24
Registration Number
NCT00289861
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

First Posted Date
2006-02-07
Last Posted Date
2011-07-25
Lead Sponsor
Nathan Kline Institute for Psychiatric Research
Target Recruit Count
46
Registration Number
NCT00287820
Locations
🇺🇸

Manhattan Psychaitric Center, New York, New York, United States

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease

Phase 3
Terminated
Conditions
Alzheimer's Disease
Dementia
First Posted Date
2006-02-07
Last Posted Date
2011-05-24
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
33
Registration Number
NCT00287742
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy